TP53 mutations were detected in 88.6% (39/44) of ESCC and 62.5% (5/8) of EAC samples, which was consistent with the observed frequencies for these mutations from a previous study (93.1% in ESCC and 72% in EAC) [12, 13]. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.